Bayer's Stock Tests a Familiar Floor as Courtroom Testimony and Farm Doubts Collide

Bayer fell 2.1% to EUR 42.95, under its 200-day average, as macro weakness and Roundup testimony add pressure before the Nov 3 Q3 report.

Bayer shares gave ground on Thursday, slipping 2.1% to EUR 42.95 as a broad retreat across European equity markets dragged the German life-sciences group to a fresh multi-month low. The decline pushed the stock just beneath its 200-day moving average of EUR 43.22, a level that had until recently served as a rough gauge of the market's medium-term confidence in the Leverkusen-based company.

The session's weakness was not a Bayer-specific story. Rising bond yields, firmer oil prices and renewed anxiety over inflation and growth weighed on benchmarks across the continent, with political uncertainty surrounding France adding to the selling pressure on German blue chips. Even after Thursday's drop, the shares remain up roughly 16% since the start of the year — a gain that now looks more vulnerable than it did a few weeks ago.

A Missouri courtroom adds to the overhang

While macro forces drove the tape, Bayer also had its own headlines to absorb. In an ongoing Roundup trial in the US state of Missouri, an oncologist took the witness stand and told the court that the herbicide was responsible for blood cancers diagnosed in three female plaintiffs. No final ruling has been issued, but the testimony serves as a reminder of the litigation exposure Bayer has carried since acquiring Monsanto — a risk that resurfaces for investors whenever such cases reach trial.

Pharma pipeline offers a counterweight

Against that legal backdrop, Bayer continues to press ahead on the pharmaceutical side. The US Food and Drug Administration has accepted a supplemental application for finerenone, marketed as Kerendia, as Bayer seeks to extend the drug's approved use to adults living with chronic kidney disease who do not have diabetes. Acceptance of the filing is a procedural step and does not amount to an approval of the additional indication.

Elsewhere in the pipeline, Lynkuet received priority review status from the FDA for treating vasomotor symptoms in breast cancer patients undergoing endocrine therapy. The company's cell-therapy arm, BlueRock Therapeutics, also secured orphan-drug designation in both the US and Europe for its candidate lemiretprocel. On the personnel front, Dr. Christoph Koenen has taken over as chief medical officer.

To underpin longer-term capacity, Bayer has earmarked USD 2.2 billion for a new pharmaceutical production site in New Albany, Ohio.

Farm economics and financing costs frame the November test

The more immediate question for shareholders concerns the agricultural division, which has become the focal point ahead of Bayer's third-quarter report on November 3, 2026. Doubts have been building in recent weeks over whether early forecasts for the quarter were set too high. JPMorgan analyst Richard Vosser flagged in late September that initial projections may have been overly optimistic, pointing to the timing of the farming cycle as the main culprit. Investors must now judge whether seasonal shifts and a difficult market for the crop-science business will weigh more heavily on group earnings than previously assumed.

Financing conditions add a further constraint. A prolonged stretch of elevated interest rates falls hardest on capital-intensive businesses, and while Bayer placed around EUR 2 billion in hybrid bonds roughly two weeks ago with maturities of six and nine years, refinancing costs remain a persistent factor in how the market values the company. Should the upcoming results confirm continued margin weakness in agriculture, the risk is that institutional investors trim their positions further — a scenario in which even encouraging drug-approval news could be overshadowed by worries about the core divisions.

What the next few weeks will settle

Technically, the stock's ability to defend its recent trading range matters. Holding above its 52-week low while absorbing the latest bout of market-wide turbulence would keep the door open to stabilization; a decisive break of the recent interim lows would clear the way for further declines. The November 3 earnings release is the next clear inflection point. A farm business that proves more resilient than feared could set the stage for a recovery toward this year's highs, while confirmation of subdued earnings would risk a longer stretch of weakness until Bayer's new pharmaceutical hopefuls begin to show through in the numbers.